Protalix BioTherapeutics/$PLX
1D1W1MYTD1Y5YMAX
About Protalix BioTherapeutics
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
- Ticker
- $PLX
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 226
- Headquarters
- Hackensack, United States
- Website
- www.protalix.com
PLX Metrics
BasicAdvanced
$192M
10.07
$0.24
0.01
-
Price and volume
Market cap
$192M
Beta
0.01
52-week high
$3.19
52-week low
$1.52
Average daily volume
686K
Financial strength
Current ratio
2.938
Quick ratio
1.821
Long term debt to equity
10.561
Total debt to equity
12.894
Interest coverage (TTM)
18.97%
Profitability
EBITDA (TTM)
24.86
Gross margin (TTM)
45.77%
Net profit margin (TTM)
23.50%
Operating margin (TTM)
28.89%
Effective tax rate (TTM)
19.26%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
15.42%
Return on equity (TTM)
31.23%
Valuation
Price to earnings (TTM)
10.066
Price to revenue (TTM)
2.352
Price to book
2.69
Price to tangible book (TTM)
2.69
Price to free cash flow (TTM)
24.726
Free cash flow yield (TTM)
4.04%
Free cash flow per share (TTM)
0.096
Growth
Revenue change (TTM)
30.14%
Earnings per share change (TTM)
205.32%
3-year revenue growth (CAGR)
6.12%
10-year revenue growth (CAGR)
35.78%
3-year earnings per share growth (CAGR)
32.09%
10-year earnings per share growth (CAGR)
-26.28%
What the Analysts think about PLX
Analyst ratings (Buy, Hold, Sell) for Protalix BioTherapeutics stock.
PLX Financial Performance
Revenues and expenses
PLX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.